Proactive Investors - Run By Investors For Investors

Summit receives financial backing to find a treatment for killer disease

Drug developer Summit has received further financial support for its quest to find a treatment for Duchenne Muscular Dystrophy, the rare muscle wasting disease that affects boys. A total of A$1.25mln has been pledged by the Australian DMD foundation, Save Our Sons.

Drug developer Summit (LON:SUMM) has received further financial support for its quest to find a treatment for Duchenne Muscular Dystrophy, the rare muscle wasting disease that affects boys.

A total of A$1.25mln has been pledged by the Australian DMD foundation, Save Our Sons (SOS).

Summit will receive A$500,000 to support the manufacture of SMT C1100, which is what’s called a utrophin modulator that reduces muscle weakness.

A further A$750,000 will be paid if there is an Australian site for patient clinical trials.

"Summit is delighted to enter this funding agreement with Save Our Sons whose generous support will help advance the clinical development of our lead utrophin modulator SMT C1100," said chief executive Glyn Edwards.

The drug is expected to enter patient clinical trials later in 2013 and has the potential to become a life-changing treatment for all DMD.

Elie Eid, founder of Save Our Sons and a DMD parent, said: "The goal of Save Our Sons is to support scientific research that aims to develop effective treatments for DMD.

“Summit's utrophin modulator SMT C1100 offers hope to all DMD boys and their families and we are delighted to be able to provide this funding to support its clinical development."

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

1550762209_shutterstock_291998651.jpg
February 21 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections
scientists in a lab
January 30 2019
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business
A man's knee pain is highlighted with a red area that points to inflammation
January 23 2019
The injectable PPS trial has had a clinically meaningful and statistically significant result in patients with arthritic knee pain.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use